MPLT

MapLight Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · maplightrx.com

$28.61

Mkt Cap $22.6M

52w Low $12.24 77.8% of range 52w High $33.28

50d MA $22.38 200d MA $19.15

P/E (TTM) -8.4x

EV/EBITDA -4.3x

P/B 3.0x

Debt/Equity 0.0x

ROE -35.2%

P/FCF -5.6x

RSI (14) —

ATR (14) —

Beta -2.79

50d MA $22.38

200d MA $19.15

Avg Volume 244.1K

About

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrita…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 26, 2026	AMC	-1.05	-2.47	-135.2%	19.23	+0.4%	-3.5%	-2.7%	+5.7%	+8.3%	+10.1%	+59.3%	—
Dec 4, 2025	AMC	-1.72	-37.18	-2061.6%	18.34	-1.3%	+0.8%	+0.6%	+2.8%	+11.3%	+9.6%	-6.1%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 4	H.C. Wainwright	Initiates	Buy	$45	$30.70	$30.55	-0.5%	-6.8%	—	—	—	—

Recent Filings

8-K

MapLight Therapeutics, Inc. -- 8-K Filing

I cannot provide a meaningful investment analysis as the filing summary lacks substantive business information regarding MapLight Therapeutics' material events or developments.

Apr 29

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

# Analysis: FTRK, MPLT Companies disclosed material information via press release and presentation on March 26, 2026, signaling potential earnings catalyst or strategic announcement—investors should review exhibits for specifics on forward guidance or operational developments affecting valuations.

Mar 26

Data updated apr 26, 2026 1:05pm · Source: massive.com